PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

PROPEL abstract — abi/pred + olaparib. Different outcomes between this trial and the MAGNITUDE trial on men withOUT HRR mutatated cancers. therefore, probably will combine parp inhibitor w/abiraterone/pred in men who are otherwise candidates for PARP inhibitors but not yet in men who are not otherwise candidates for PARP inhibitor therapy.

Read the full article here

Related Articles